Page 240 - 2021_04-Haematologica-web

H. Al-Samkari et al.
ed by improved platelet counts and low rates of chemotherapy dose reductions and treatment delays, bleeding, and platelet transfusions. VTE rates approximat- ed rates in similar cancer populations not receiving romi- plostim. Weekly dosing resulted in improved outcomes as compared with more intermittent intracycle dosing. Romiplostim was generally ineffective in patients with BM invasion by tumor, prior pelvic irradiation, and prior exposure to temozolomide.
Disclosures
HA-S has had a consultancy role for Agios, Dova, Rigel, Argenx, and Sobi, and has received research funding from Agios, Dova, and Amgen; ADP has had a consultancy role for Sunovion, has received research funding from Genentech/Hoffman LaRoche, and Shire/Takeda, and sits on the scientific advisory boards of Bayer, and Shire/Takeda; JIW has had a consultancy role for AbbVie; JMC sits on the scientific advisory boards of Bristol-Myers Squibb, and Portola, has had a consultancy role for Bristol-Myers Squibb, has received personal fees from Bristol-Myers Squibb, and sits on the data safety mon- itoring board of Unum Therapeutics; DJK has received research funding from Protalex, Bristol-Myers Squibb, Rigel, Bioverativ, Agios, Syntimmune, Principia, and Alnylam, and has had a con- sultancy role for ONO, Pfizer, 3SBios, Eisai, GlaxoSmithKline,
Genzyme, Shire, Amgen, Shionogi, Rigel, Syntimmune, MedImmune, Novartis, Alexion, Bioverativ, Argenx, Zafgen, Fujifilm, Principia, Kyowa Kirin, Takeda, and the Platelet Disorders Support Association.
Contributions
HA-S wrote the first draft of the manuscript and contributed to study design, data collection, data analysis, creation of tables and figures, critical revision of the manuscript, and final approval of the manuscript for publication; ADP contributed to romiplostim treatment pathway design, data collection, revision of the manu- script, and final approval of the manuscript for publication; KG, JIW and JMC contributed to romiplostim treatment pathway design, revision of the manuscript, and final approval of the man- uscript for publication; DJK contributed to romiplostim treatment pathway design, critical revision of the manuscript, and final approval of the manuscript for publication.
Acknowledgments
Hemophilia Foundation-Shire Clinical Fellowship Award, the Harvard Catalyst Medical Research Investigator Training Award, and the American Society of Hematology Scholar Award. We also acknowledge the Harvard Catalyst Biostatistics Team, and in particular Dr. Douglas Hayden, for biostatistical support in this study.
References
1. Kuter DJ. Managing thrombocytopenia associated with cancer chemotherapy. Oncology (Williston Park). 2015;29(4):282- 294.
2. Wu Y, Aravind S, Ranganathan G, Martin A, Nalysnyk L. Anemia and thrombocy- topenia in patients undergoing chemother- apy for solid tumors: a descriptive study of a large outpatient oncology practice data- base, 2000-2007. Clin Ther. 2009;31 Pt 2:2416-2432.
3. Denduluri N, Patt DA, Wang Y, et al. Dose delays, dose reductions, and relative dose intensity in patients with cancer who received adjuvant or neoadjuvant chemotherapy in community oncology practices. J Natl Compr Canc Netw. 2015;13(11):1383-1393.
4. Elting LS, Rubenstein EB, Martin CG, et al. Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol. 2001;19(4):1137-1146.
5. Moskowitz CH, Hamlin PA, Gabrilove J, et al. Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a sur- vival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma. Ann Oncol. 2007;18(11):1842-1850.
6.Aspinall SL, Good CB, Zhao X, et al. Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans. BMC Cancer. 2015;15:62.
7.Havrilesky LJ, Reiner M, Morrow PK, Watson H, Crawford J. A review of relative dose intensity and survival in patients with metastatic solid tumors. Crit Rev Oncol Hematol. 2015;93(3):203-210.
8. Hanna RK, Poniewierski MS, Laskey RA, et al. Predictors of reduced relative dose inten- sity and its relationship to mortality in
women receiving multi-agent chemothera- py for epithelial ovarian cancer. Gynecol Oncol. 2013;129(1):74-80.
9. Kuter DJ, Rummel M, Boccia R, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med. 2010;363(20):1889-1899.
10. Townsley DM, Scheinberg P, Winkler T, et al. Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med. 2017;376(16):1540-1550.
11. Afdhal NH, Dusheiko GM, Giannini EG, et al. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effec- tive antiviral therapy. Gastroenterology. 2014;146(2):442-452 e441.
12. Al-Samkari H, Marshall AL, Goodarzi K, Kuter DJ. Romiplostim for the manage- ment of perioperative thrombocytopenia. Br J Haematol. 2018;182(1):106-113.
13.Terrault N, Chen YC, Izumi N, et al. Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocy- topenia. Gastroenterology. 2018; 155(3):705-718.
14. Tateishi R, Seike M, Kudo M, et al. A ran- domized controlled trial of lusutrombopag in Japanese patients with chronic liver dis- ease undergoing radiofrequency ablation. J Gastroenterol. 2018;54(2):171-181.
15. Kumagai Y, Fujita T, Ozaki M, et al. Pharmacodynamics and pharmacokinetics of AMG 531, a thrombopoiesis-stimulating peptibody, in healthy Japanese subjects: a randomized, placebo-controlled study. J Clin Pharmacol. 2007;47(12):1489-1497.
16. Jenkins JM, Williams D, Deng Y, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor ago- nist. Blood. 2007;109(11):4739-4741.
17. Nomoto M, Pastino G, Rege B, Aluri J, Ferry J, Han D. Pharmacokinetics, pharma- codynamics, pharmacogenomics, safety, and tolerability of avatrombopag in healthy
Japanese and white subjects. Clin
Pharmacol Drug Dev. 2018;7(2):188-195. 18. Parameswaran R, Lunning M, Mantha S, et al. Romiplostim for management of chemotherapy-induced thrombocytopenia. Support Care Cancer. 2014;22(5):1217-
1222.
19. Miao J, Leblebjian H, Scullion B, Parnes A.
A single center experience with romi- plostim for the management of chemother- apy-induced thrombocytopenia. Am J Hematol. 2018;93(4):E86-E88.
20. Al-Samkari H, Marshall AL, Goodarzi K, Kuter DJ. The use of romiplostim in treat- ing chemotherapy-induced thrombocy- topenia in patients with solid tumors. Haematologica. 2018;103(4):e169-e172.
21.Soff GA, Miao Y, Bendheim G, et al. Romiplostim treatment of chemotherapy- induced thrombocytopenia. J Clin Oncol. 2019;37(31):2892-2898.
22. Tepler I, Elias L, Smith JW 2nd, et al. A ran- domized placebo-controlled trial of recom- binant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood. 1996; 87(9):3607-3614.
23. Vadhan-Raj S, Verschraegen CF, Bueso- Ramos C, et al. Recombinant human thrombopoietin attenuates carboplatin- induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med. 2000;132(5):364-368.
24.Basser RL, Underhill C, Davis I, et al. Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer. J Clin Oncol. 2000;18(15):2852-2861.
25. Neumann TA, Foote M. Megakaryocyte growth and development factor (MGDF): an Mpl ligand and cytokine that regulates thrombopoiesis. Cytokines Cell Mol Ther. 2000;6(1):47-56.
1156
haematologica | 2021; 106(4)